{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T16:25:06Z","timestamp":1791563106351,"version":"4.3.4"},"reference-count":37,"publisher":"The Endocrine Society","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,6,1]]},"abstract":"<jats:sec>\n                  <jats:title>Context and Objective:<\/jats:title>\n                  <jats:p>The histrelin implant has proven to be an effective method of delivering GnRH analog (GnRHa) therapy to children with central precocious puberty (CPP), yet there are limited data available regarding hormonal suppression and auxological changes during an extended course of therapy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Design:<\/jats:title>\n                  <jats:p>This was a phase 3, prospective, open-label study.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Setting and Participants:<\/jats:title>\n                  <jats:p>Thirty-six children with CPP who participated in a phase 3, open-label study and required further GnRHa therapy were eligible to continue treatment receiving a new implant upon removal of the prior 12-month histrelin implant during a long-term extension phase.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Outcome Measures:<\/jats:title>\n                  <jats:p>Hormone levels and auxologic parameters were measured periodically for up to 6 years of treatment and up to 1 year of posttreatment follow-up.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results:<\/jats:title>\n                  <jats:p>Hormonal suppression was maintained throughout the study in patients who had prior GnRHa therapy (n = 16) and in treatment-naive patients (n = 20). Bone age to chronological age ratio decreased from 1.417 (n = 20) at baseline to 1.18 (n = 8) at 48 months in treatment-naive children (P &amp;lt; .01). Predicted adult height in girls increased from 151.9 cm at baseline to 166.5 cm at month 60 (n = 6; P &amp;lt; .05), with a 10.7-cm height gain observed among treatment-naive children (n = 5). No adverse effect on growth or recovery of the hypothalamic-pituitary-gonadal axis was observed with hormonal suppression. The histrelin implant was generally well tolerated during long-term therapy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions:<\/jats:title>\n                  <jats:p>Long-term histrelin implant therapy provided sustained gonadotropin suppression safely and effectively and improved predicted adult height in children with CPP.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1210\/jc.2014-3031","type":"journal-article","created":{"date-parts":[[2015,3,24]],"date-time":"2015-03-24T17:08:14Z","timestamp":1427216894000},"page":"2354-2363","source":"Crossref","is-referenced-by-count":60,"title":["Long-Term Continuous Suppression With Once-Yearly Histrelin Subcutaneous Implants for the Treatment of Central Precocious Puberty: A Final Report of a Phase 3 Multicenter Trial"],"prefix":"10.1210","volume":"100","author":[{"given":"Lawrence A.","family":"Silverman","sequence":"first","affiliation":[{"name":"Division of Pediatric Endocrinology (L.A.S.), Goryeb Children's Hospital Atlantic Health, Morristown, New Jersey 07962"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. Kirk","family":"Neely","sequence":"additional","affiliation":[{"name":"Division of Pediatric Endocrinology and Diabetes (E.K.N.), Stanford University, Stanford, California 94305-5208"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gad B.","family":"Kletter","sequence":"additional","affiliation":[{"name":"Redmond (G.B.K.), Washington 98052"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Lewis","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Diabetes, and Medical Genetics (K.L.), Charleston, South Carolina 29425"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Surya","family":"Chitra","sequence":"additional","affiliation":[{"name":"Endo Pharmaceuticals Inc (S.C., O.T.), Malvern, Pennsylvania 19355"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oksana","family":"Terleckyj","sequence":"additional","affiliation":[{"name":"Endo Pharmaceuticals Inc (S.C., O.T.), Malvern, Pennsylvania 19355"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica A.","family":"Eugster","sequence":"additional","affiliation":[{"name":"Riley Hospital for Children at Indiana University Health (E.A.E.), Indianapolis, Indiana 46202"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","reference":[{"key":"2020071615592525500_B1","doi-asserted-by":"crossref","first-page":"e752","DOI":"10.1542\/peds.2008-1783","article-title":"Consensus statement on the use of gonadotropin-releasing hormone analogs in children","volume":"123","author":"Carel","year":"2009","journal-title":"Pediatrics"},{"key":"2020071615592525500_B2","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1186\/1471-2458-9-446","article-title":"Early pubertal onset and its relationship with sexual risk taking, substance use and anti-social behaviour: a preliminary cross-sectional study","volume":"9","author":"Downing","year":"2009","journal-title":"BMC Public Health"},{"key":"2020071615592525500_B3","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1037\/a0024008","article-title":"Elevated social anxiety among early maturing girls","volume":"47","author":"Blumenthal","year":"2011","journal-title":"Dev Psychol"},{"key":"2020071615592525500_B4","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1111\/j.1651-2227.2001.tb01349.x","article-title":"Psychological assessments before and after treatment of early puberty in adopted children","volume":"90","author":"Mul","year":"2001","journal-title":"Acta Paediatr"},{"key":"2020071615592525500_B5","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1111\/j.1651-2227.1997.tb08602.x","article-title":"Longitudinal study of behavioral and affective patterns in girls with central precocious puberty during long-acting triptorelin therapy","volume":"86","author":"Xhrouet-Heinrichs","year":"1997","journal-title":"Acta Paediatr"},{"key":"2020071615592525500_B6","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1053\/beem.2002.0188","article-title":"Treatment of central precocious puberty","volume":"16","author":"Partsch","year":"2002","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"2020071615592525500_B7","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1530\/EJE-08-0814","article-title":"The use of GnRH agonists in precocious puberty","volume":"159","author":"Mul","year":"2008","journal-title":"Eur J Endocrinol"},{"key":"2020071615592525500_B8","doi-asserted-by":"crossref","first-page":"4111","DOI":"10.1210\/jc.2001-020243","article-title":"Treatment of central precocious puberty by subcutaneous injections of leuprorelin 3-month depot (11.25 mg)","volume":"87","author":"Carel","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071615592525500_B9","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/S0022-3476(05)81720-2","article-title":"Local reactions to depot leuprolide therapy for central precocious puberty","volume":"123","author":"Manasco","year":"1993","journal-title":"J Pediatr"},{"key":"2020071615592525500_B10","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/S0022-3476(05)81162-X","article-title":"Two-year results of treatment with depot leuprolide acetate for central precocious puberty","volume":"121","author":"Neely","year":"1992","journal-title":"J Pediatr"},{"key":"2020071615592525500_B11","first-page":"1","article-title":"Experience with the once-yearly histrelin (GnRHa) subcutaneous implant in the treatment of central precocious puberty","volume":"3","author":"Lewis","year":"2009","journal-title":"Drug Des Devel Ther"},{"key":"2020071615592525500_B12","doi-asserted-by":"crossref","first-page":"e798","DOI":"10.1542\/peds.2005-0538","article-title":"The histrelin implant: a novel treatment for central precocious puberty","volume":"116","author":"Hirsch","year":"2005","journal-title":"Pediatrics"},{"key":"2020071615592525500_B13","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1210\/jc.2006-2479","article-title":"Efficacy and safety of histrelin subdermal implant in children with central precocious puberty: a multicenter trial","volume":"92","author":"Eugster","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071615592525500_B14","doi-asserted-by":"crossref","first-page":"812517","DOI":"10.1186\/1687-9856-2009-812517","article-title":"Results of a second year of therapy with the 12-month histrelin implant for the treatment of central precocious puberty","volume":"2009","author":"Rahhal","year":"2009","journal-title":"Int J Pediatr Endocrinol"},{"key":"2020071615592525500_B15","doi-asserted-by":"crossref","first-page":"2198","DOI":"10.1210\/jc.2013-1024","article-title":"Treatment and outcomes of precocious puberty: an update","volume":"98","author":"Fuqua","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071615592525500_B16","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/j.jpeds.2013.05.033","article-title":"A single histrelin implant is effective for 2 years for treatment of central precocious puberty","volume":"163","author":"Lewis","year":"2013","journal-title":"J Pediatr"},{"key":"2020071615592525500_B17","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1056\/NEJMcp0800459","article-title":"Clinical practice. Precocious puberty","volume":"358","author":"Carel","year":"2008","journal-title":"N Engl J Med"},{"key":"2020071615592525500_B18","doi-asserted-by":"crossref","first-page":"398639","DOI":"10.1186\/1687-9856-2010-398639","article-title":"Leuprolide acetate 1-month depot for central precocious puberty: hormonal suppression and recovery","volume":"2010","author":"Neely","year":"2010","journal-title":"Int J Pediatr Endocrinol"},{"key":"2020071615592525500_B19","first-page":"653","article-title":"Long-term effectiveness of depot gonadotropin-releasing hormone analogue in the treatment of children with central precocious puberty","volume":"147","author":"Clemons","year":"1993","journal-title":"Am J Dis Child"},{"key":"2020071615592525500_B20","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1687-9856-2011-7","article-title":"Efficacy of leuprolide acetate 1-month depot for central precocious puberty (CPP): growth outcomes during a prospective, longitudinal study","volume":"2011","author":"Lee","year":"2011","journal-title":"Int J Pediatr Endocrinol"},{"key":"2020071615592525500_B21","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1210\/jc.2004-1863","article-title":"Results of long-term follow-up after treatment of central precocious puberty with leuprorelin acetate: evaluation of effectiveness of treatment and recovery of gonadal function. The TAP-144-SR Japanese Study Group on Central Precocious Puberty","volume":"90","author":"Tanaka","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071615592525500_B22","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/j.jpeds.2011.05.036","article-title":"A randomized trial of 1- and 3-month depot leuprolide doses in the treatment of central precocious puberty","volume":"159","author":"Fuld","year":"2011","journal-title":"J Pediatr"},{"key":"2020071615592525500_B23","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1007\/s11596-006-0519-2","article-title":"Efficacy of subcutaneous administration of gonadotropin-releasing hormone agonist on idiopathic central precocious puberty","volume":"26","author":"Liang","year":"2006","journal-title":"J Huazhong Univ Sci Technolog Med Sci"},{"key":"2020071615592525500_B24","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1515\/JPEM.2003.16.7.1005","article-title":"Effects of combined gonadotropin-releasing hormone agonist and growth hormone therapy on adult height in precocious puberty: a further contribution","volume":"16","author":"Pucarelli","year":"2003","journal-title":"J Pediatr Endocrinol Metab"},{"key":"2020071615592525500_B25","doi-asserted-by":"crossref","first-page":"3153","DOI":"10.1210\/jc.2013-4471","article-title":"36-month treatment experience of two doses of leuprolide acetate 3-month depot for children with central precocious puberty","volume":"99","author":"Lee","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071615592525500_B26","doi-asserted-by":"crossref","first-page":"2841","DOI":"10.1210\/jc.2009-2078","article-title":"Free \u03b1-subunit is the most sensitive marker of gonadotropin recovery after treatment of central precocious puberty with the histrelin implant","volume":"95","author":"Hirsch","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071615592525500_B27","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.jpeds.2013.01.021","article-title":"Time to menarche and final height after histrelin implant treatment for central precocious puberty","volume":"163","author":"Gillis","year":"2013","journal-title":"J Pediatr"},{"key":"2020071615592525500_B28","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1016\/j.jpeds.2013.12.009","article-title":"Resumption of puberty in girls and boys following removal of the histrelin implant","volume":"164","author":"Fisher","year":"2014","journal-title":"J Pediatr"},{"key":"2020071615592525500_B29","volume-title":"Assessing the Skeletal Maturity of the Hand Wrist: Fels Method","author":"Roche","year":"1988"},{"key":"2020071615592525500_B30","unstructured":"National Center for Health Statistics. 2000CDC growth charts: United States. http:\/\/www.cdc.gov\/growthcharts. Accessed December 11, 2014"},{"key":"2020071615592525500_B31","unstructured":"Children's Hospital. Growth Calculator, version 2.01, Children's Hospital, Boston, MA. http:\/\/growthcalc.chip.org. Accessed December 11, 2014"},{"key":"2020071615592525500_B32","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/1687-9856-2013-20","article-title":"Random unstimulated pediatric luteinizing hormone levels are not reliable in the assessment of pubertal suppression during histrelin implant therapy","volume":"2013","author":"Neely","year":"2013","journal-title":"Int J Pediatr Endocrinol"},{"key":"2020071615592525500_B33","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.jpeds.2012.08.038","article-title":"Random luteinizing hormone often remains pubertal in children treated with the histrelin implant for central precocious puberty","volume":"162","author":"Lewis","year":"2013","journal-title":"J Pediatr"},{"key":"2020071615592525500_B34","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1210\/jc.2011-2704","article-title":"Efficacy and safety of leuprolide acetate 3-month depot 11.25 milligrams or 30 milligrams for the treatment of central precocious puberty","volume":"97","author":"Lee","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071615592525500_B35","doi-asserted-by":"crossref","first-page":"27","DOI":"10.4068\/cmj.2012.48.1.27","article-title":"Effects of gonadotropin-releasing hormone agonist therapy on body mass index and height in girls with central precocious puberty","volume":"48","author":"Lee","year":"2012","journal-title":"Chonnam Med J"},{"key":"2020071615592525500_B36","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1093\/humupd\/dmh012","article-title":"Precocious puberty and statural growth","volume":"10","author":"Carel","year":"2004","journal-title":"Hum Reprod Update"},{"key":"2020071615592525500_B37","doi-asserted-by":"crossref","first-page":"524","DOI":"10.3109\/09513590.2010.507289","article-title":"Adult height, body mass index and time of menarche of girls with idiopathic central precocious puberty after gonadotropin-releasing hormone analogue treatment","volume":"27","author":"Poomthavorn","year":"2011","journal-title":"Gynecol Endocrinol"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/100\/6\/2354\/10422775\/jcem2354.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/100\/6\/2354\/10422775\/jcem2354.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,17]],"date-time":"2020-07-17T03:03:22Z","timestamp":1594955002000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/100\/6\/2354\/2829637"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6,1]]},"references-count":37,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,6,1]]}},"URL":"https:\/\/doi.org\/10.1210\/jc.2014-3031","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,6,1]]}}}